Royal Philips announced a major advance in radiation oncology with 510(k) clearance from the US Food and Drug Administration (FDA) for its new detector-based spectral CT radiotherapy solution.
A bit more mucus in the nose, a little less air in the gut: Even small changes can be important when planning proton therapy against cancer. A new workflow allows for an adapted irradiation every day.
Smaller kills faster – this is what was previously thought about gold nanoparticles used to fight cancer cells. However, new research reveals a more complex picture of these interactions.
The concept of delivering radiation therapy to cancer patients seated in an upright position is undergoing a major resurgence. Evidence is already highlighting that patients feel more comfortable seated upright and enjoy better communication with radiotherapists during their care. In addition, there are indications of less internal organ movement, enabling more accurate treatment delivery.…
An Italian research team has introduced a new MRI-based method for assessing water water exchange to estimate the degree of malignancy and the success of treatments in tumors.
For proton radiation therapy against cancer, there is yet no direct method for mapping the beam range during dose delivery. A new method devised by Dresden scientists could help.
An artificial intelligence (AI) model combining four methods of machine learning (ML) to accurately detect thyroid cancer from routine ultrasound image data has been developed by US researchers.
A new research venture pairs cutting-edge particle accelerator science and radiation therapy.
Researchers at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) want to build the world’s first prototype that tracks moving tumors with magnetic resonance imaging (MRI) in real time during proton therapy. They are combining a rotating open MRI device, designed for the LINAC-MR system from Alberta Health Services, with an actively scanned clinical-akin proton beam at OncoRay, the Dresden-based…
A radiotherapy technique which ‘paints’ tumours by targeting them precisely, and avoiding healthy tissue, has been devised in research led by the University of Strathclyde. Researchers used a magnetic lens to focus a Very High Electron Energy (VHEE) beam to a zone of a few millimetres. Concentrating the radiation into a small volume of high dose will enable it to be rapidly scanned across a…
A promising approach to treating cancer—called targeted alpha-particle therapy or TAT—could better harness the curative power of radiation treatments and lessen the severity of their more debilitating side effects.
To target ionised radiation as precisely as possible, imaging a tumour is vital in radiotherapy planning. ‘Today, imaging is used increasingly during the therapy itself,’ explained Professor Mark Ladd during the 51st annual meeting of the German Society for Medical Physics (DGMP).
A new way of concentrating radiotherapy dose in tumours, while minimising damage to healthy cells, has been proposed in research led by scientists at the University of Strathclyde. The study proposes that focusing high-energy particle beams on a small spot deep inside the body could potentially enable clinicians to target cancerous tumours precisely, while reducing the dose to surrounding tissue.…
Within a groaning 140-tonne particle accelerator a patient receives proton therapy, whilst down a few corridors, acupuncture needles are being placed and herbs mixed. Tradition and high tech walk hand in hand in Taiwanese healthcare. That’s what we learn during our visit to several facilities near Taipei.
IBA (Ion Beam Applications S.A.) announces the launch of myQA iON at the 2019 PTCOG conference. myQA iON significantly reduces the time needed for patient QA: The use of PT machine log files, process automation, task-based workflows, and the latest web technologies significantly increase QA efficiency while ensuring patient treatment safety. Compared to conventional detector measurements (at…
IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy solutions and radiation therapy integrated quality assurance (QA) for the treatment of cancer, announced at the ESTRO 38 congress, that it has reached the milestone of 1,500 myQA customers worldwide. Since the first release of myQA in 2015, IBA has rapidly expanded its customer base across the global radiation…
IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy solutions and radiation therapy integrated quality assurance (QA) for the treatment of cancer, announces the successful commissioning of the Varian Halcyon at the Radiation Oncology Center at MedStar Southern Maryland Hospital Center, based on IBA Dosimetry independent beam scanning solution. IBA has designed myQA…
New accelerator-based technology being developed by the Department of Energy’s SLAC National Accelerator Laboratory and Stanford University aims to reduce the side effects of cancer radiation therapy by shrinking its duration from minutes to under a second. Built into future compact medical devices, technology developed for high-energy physics could also help make radiation therapy more…
IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy solutions and radiation therapy integrated quality assurance (QA) for the treatment of cancer, announces that it has entered into an agreement with Varian with the goal of validating the Dolphin transmission detector for online monitoring of patient treatment. With the health, security and safety of patients in…
Hitachi, Ltd. announced that it has entered into an agreement to provide Clinica Universidad de Navarra (CUN) with its proton beam therapy (PBT) system. The agreement includes PBT system maintenance following completion of the systems' installation. The PBT System will be installed at CUN's facility in Madrid, Spain and is equipped with state of the art technology including spot scanning…
IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy solutions and radiation therapy integrated quality assurance (QA) for the treatment of cancer, announces the acceptance and beam model validation of the first Varian Halcyon machine in Europe to go clinical, at the hospital UZ Leuven in Belgium, using IBA Dosimetry’s Blue Phantom water phantom system.
IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy solutions and radiation therapy integrated quality assurance (QA) for the treatment of cancer, announces the release of myQA version 2017-001. This new version further enhances the integration of quality assurance across all QA applications, departments and people.
IBA (Ion Beam Applications) today unveils its unique platform, 'Leading the PATh', which gathers the leading experts in the field of proton therapy all in one place. It is anticipated that 'Leading the PATh' will enable the worldwide medical community to shape the most efficient Proton Adaptive Therapy (PATh), a proton therapy process which improves the accuracy of what is considered to be the…
With its previous LCMS-8030, LCMS-8040 and LCMS-8050 triple-quadrupole systems, Shimadzu has set leading standards in terms of speed, sensitivity and functional design. With the introduction of the new LCMS-8060 (Figure 1), the success story of the LCMS-triple-quadrupole family reaches another milestone.
A global collaboration to expand access to advanced particle therapy worldwide was agreed this April between Belgian firm IBA (Ion Beam Applications S.A.) and the Toshiba Corporation.
Physicians often blame patient demands for contributing to high medical costs, however, a new study involving more than 5,000 patient-clinician visits indicates that cancer patients rarely push for unnecessary tests and treatments from their health care providers.
IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that it has signed final contracts concluding the Essen project negotiation with the University Hospital of Essen (UK Essen).
A major new cutting edge radiotherapy treatment will be available in the UK thanks to £250 million of government funding to build two new facilities in Manchester and London, Public Health Minister Anna Soubry confirmed on August, 1.
PBT uses a high-energy beam of particles to destroy cancer cells by more accurately targeting the affected areas and is particularly suitable for complex childhood cancers. It also increases success rates and reduces side effects, such as deafness, loss of IQ and secondary cancers.
Currently there is a truly enormous hole in the ground in the city of Wiener Neustadt, Austria, but by summer 2012 MedAustron, one of the most modern centres for ion therapy and research in Europe, is to be built here.
A combination of several well-known safety procedures could greatly reduce patient-harming errors in the use of radiation to treat cancer, according to a new study led by Johns Hopkins researchers.
A major public hospital has become the first in Paris to be equipped with a Gamma Knife, the device that enables the surgeon to operate on the brain with no blade or blood involved.
As one of the most advanced forms of precision radiotherapy, proton therapy enables the irradiation of tumours located deep within the body, in the proximity of critical organs, such as the optic nerve or some brain areas. The Institut Curie has renovated its proton therapy centre in Orsay near Paris. Since 1991, when the original centre opened, it has treated over 5,000 patients (4,000 for eye…
The world consists of molecules – so do we. With the progression of measurement tools such as microscopes, centrifuges, or spectrometers, mankind is becoming better and better in identifying the substances from which our world is made. Today, with the technical developments in mass spectrometry, biomolecules can be weighted with the highest precision and accuracy ever known, placing it among…
During his Honorary Lecture at the 8th Düsseldorf Breast Cancer Conference in Germany world renowned surgeon and oncologist Prof. Veronesi reflected about the prevention and treatment of breast cancer.
Italian surgeon and oncologist Prof. Dr. Umberto Veronesi, Founder and Scientific Director of the European Institute of Oncology in Milan and former National Health Minister (2000 – 2001), is considered to be one of the biggest authorities on breast cancer research of our time. Many breakthrough changings in cancer medicine sustainably go back on his researches, which once earned him also a…
Agenzia Provinciale Per la Protonterapia (ATreP) has signed a contract with Ion Beam Applications S.A. (IBA), based in Luvain-La-Neuve, Belgium, for the installation of a proton therapy centre in a new hospital planned for Trento. Over the next 15 years, IBA will provide the construction, installation and technical operation of this the first gantry-equipped proton therapy-dedicated centre in…
When we organised the first Diagnostic Week in Karlsruhe, in 1969, no one could have known that this event would one day turn into the annual highlight in the world of medicine, reflected Dr Wolfgang Albath, laboratory medicine pioneer and one of the founding fathers of MEDICA the world`s largest medical trade show. Initially planned as a moving exhibition, the show has been based in…
Although the potential of proton therapy was recognised over half a century ago, and since its development is now known to deliver a radiation beam accurately into a tumour without damaging surrounding tissue, high equipment costs limit its general introduction. Mark Nicholls reports on a British hospital with two decades of experience in its use - and value
Proton therapy is very sophisticated way of destroying tumours. Now the Swedish Medical company RaySearch Laboratories has signed a consulting agreement with Uppsala University Hospital in Sweden to develop a treatment-planning system.